---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-003372"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:18:48.593320+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Dermata's XYNGARI Phase 3 acne trial meets all primary endpoints with statistical significance

## Summary
- STAR-1 achieved all three primary endpoints: IGA success 29.4% vs 15.2% placebo (p<0.001).
- Inflammatory lesion count reduced by 16.8 vs 13.1 (p<0.001); non-inflammatory by 17.3 vs 12.4 (p<0.001).
- XYNGARI safe and well tolerated; no serious treatment-related adverse events.
- Plans to initiate second Phase 3 STAR-2 trial in H2 2025, followed by NDA submission if positive.
- CEO cites potential for partnership discussions; over 30 million U.S. acne patients annually.

## SEC filing metadata
- accession: 0001654954-25-003372
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495425003372/0001654954-25-003372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495425003372/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-003372
- JSON: https://secwatch.observer/filing/0001654954-25-003372.json
- Plain text: https://secwatch.observer/filing/0001654954-25-003372.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.